TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9461944

Group type: EXPERIMENTAL
Intervention: 12.5 mg/kg ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5 ml/kg of standard oral premedication (SOP)
Number of subjects: 60
Study: 14621723

Group type: EXPERIMENTAL
Intervention: Monoclonal immunoglobulins (mIg) identified by agarose gel electrophoresis and immunofixation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Identified predisposing factors for mIg emergence
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Serological evidence for active EBV infection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Clinical course of patients with mIg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Regulatory T-cell function
Number of subjects: 192
Study: 2864892

Group type: EXPERIMENTAL
Intervention: Propranolol (11 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Hexamethonium (910 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30621047

Group type: EXPERIMENTAL
Intervention: Sanghuang⁻Danshen (SD) bioactives at 900 mg/day for 4 weeks
Number of subjects: 72
Study: 28657863

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (50g glucose before each training bout)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No carbohydrate intake (control)
Number of subjects: 23
Study: 26725922

Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bonfils intubation fiberscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 30
Study: 24473467

Group type: EXPERIMENTAL
Intervention: Combined strength and high-intensity training (S group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 24
Study: 22791244

Group type: EXPERIMENTAL
Intervention: Test formulation (dispersible tablet)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (branded capsule)
Number of subjects: 18
Study: 20112368

Group type: EXPERIMENTAL
Intervention: Org 37663 (4 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 37663 (15 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 37663 (50 mg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18173153

Group type: EXPERIMENTAL
Intervention: TCM treatment for dissolving phlegm and dispelling stasis (DP‐DS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 122
Study: 16248138

Group type: EXPERIMENTAL
Intervention: Cognitive imaging as a teaching method
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional instructional techniques
Number of subjects: 42
Study: 11896446

Group type: EXPERIMENTAL
Intervention: Vero-IL-2 (5x10^5 cells)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vero-IL-2 (5x10^6 cells)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vero-IL-2 (both doses)
Number of subjects: 28
Study: 10629245

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 9019380

Group type: EXPERIMENTAL
Intervention: 0.1 ml Healon injected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 ml Healon injected
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon aspirated
Number of subjects: 0
Study: 1761331

Group type: EXPERIMENTAL
Intervention: Captopril (intervention)
Number of subjects: 0
Study: 6803118

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (ad libitum intake)
Number of subjects: 0
Study: 30864054

Group type: EXPERIMENTAL
Intervention: High nicotine dependence (measured by FTND)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Expired CO levels
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Prepared to change
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Confidence to quit
Number of subjects: 255
Study: 29900874

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg orally twice daily
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1754
Study: 27692272

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 12 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo nightly for 12 months
Number of subjects: 95
Study: 24588623

Group type: COMPARATOR
Intervention: Inflow tract implantation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mid-septum implantation
Number of subjects: 80
Study: 22738796

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine-based acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham acupuncture with Streitberger placebo needles
Number of subjects: 50
Study: 20647199

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² per week for 4 weeks)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclophosphamide (2 mg/kg per day)
Number of subjects: 197
Study: 17209171

Group type: EXPERIMENTAL
Intervention: Vitamin D dose > or = 250 microg/d (10,000 IU vitamin D3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current UL for vitamin D (50 microg, or 2000 IU)
Number of subjects: 0
Study: 16275247

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12019667

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 37
Study: 10633642

Group type: EXPERIMENTAL
Intervention: Music listening intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 30
Study: 7546499

Group type: COMPARATOR
Intervention: enalapril/placebo (group I)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 6 mg enalapril/HCTZ (group II)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 12.5 mg enalapril/HCTZ (group III)
Number of subjects: 296
Study: 2187213

Group type: EXPERIMENTAL
Intervention: Lorazepam (mean daily dose of 7 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose of 3 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 213186

Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in addition to conventional therapy (surgery, radiotherapy or no treatment)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment with a full course of radiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in patients with squamous carcinoma
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in patients with oat cell carcinoma
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparable groups of patients with squamous carcinoma
Number of subjects: 75
Study: 31338688

Group type: COMPARATOR
Intervention: SAGE-217 (0.25 to 66 mg single dose)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SAGE-217 (15, 30, or 35 mg once daily for 7 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SAGE-217
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 31175210

Group type: EXPERIMENTAL
Intervention: e-STI testing and results service
Number of subjects: 528
Study: 28060921

Group type: EXPERIMENTAL
Intervention: Integrated Care Group (ICG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 0
Study: 25502343

Group type: EXPERIMENTAL
Intervention: Antegrade intramedullary pinning
Number of subjects: 46

Group type: COMPARATOR
Intervention: Percutaneous retrograde intramedullary pinning
Number of subjects: 46
Study: 24196337

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5%
Number of subjects: 479

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 479
Study: 22687548

Group type: EXPERIMENTAL
Intervention: Cognitive remediation condition including the Posit Science Brain Fitness auditory training program with weekly Neuropsychological and Educational Approach to Remediation (NEAR) 'bridging groups'
Number of subjects: 53

Group type: COMPARATOR
Intervention: Computer games and weekly healthy lifestyles groups (control condition)
Number of subjects: 53
Study: 19050635

Group type: EXPERIMENTAL
Intervention: NIPPVf (face mask)
Number of subjects: 90

Group type: COMPARATOR
Intervention: NIPPVn (nasal mask)
Number of subjects: 90
Study: 17514524

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive (Quixil) (n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vicryl sutures (n = 39)
Number of subjects: 81
Study: 15528583

Group type: EXPERIMENTAL
Intervention: Wireless networked mobile computer (MC)
Number of subjects: 10
Study: 11851739

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections (up to 4.0 U BOTOX/kg/muscle, 16 U/kg/body weight every 6 months) plus SWASH brace
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (clinical best practice physiotherapy without hip abduction bracing)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined treatment (BTX‐A/SWASH)
Number of subjects: 39
Study: 9611669

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 +/- 2.5 mg)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine (15 +/- 2.5 mg)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Haloperidol (10-20 mg)
Number of subjects: 335
Study: 8555592

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Plasma Perfusion (PP)
Number of subjects: 22
Study: 3295299

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29735019

Group type: EXPERIMENTAL
Intervention: EPA+DHA therapy (2.5 g/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 35
Study: 27195316

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 23892501

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei SD1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard milk powder (placebo)
Number of subjects: 40
Study: 22656676

Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine (11.25mg) + 2mL dextrose (5mg.mL(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypobaric ropivacaine (11.25mg) + 2mL distilled water
Number of subjects: 60
Study: 19732091

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pulse Dexamethasone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (Standard Critical Care)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall Mortality
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Serum Bilirubin Level
Number of subjects: 68
Study: 18729814

Group type: EXPERIMENTAL
Intervention: Carnosine (beta‐alanyl‐L‐histidine) as a food additive
Number of subjects: 0
Study: 15986953

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coltosol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CLIP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ag-IRM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ag-CLIP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Co-IRM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Co-CLIP
Number of subjects: 45
Study: 12414399

Group type: EXPERIMENTAL
Intervention: HOTL (daily wear)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control lens (daily wear)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HOTL (extended wear)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control lens (extended wear)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HOTL (extended wear, 6 nights)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HOTL (extended wear, 30 nights)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both lenses (daily wear)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both lenses (extended wear)
Number of subjects: 168
Study: 10359479

Group type: EXPERIMENTAL
Intervention: ipsapirone 0.3 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 8961905

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 264
Study: 1782977

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin every 4 hours
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin for 24 hours
Number of subjects: 29
Study: 6293720

Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively and for 24 hours postoperatively
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cefazolin perioperatively and for 24 hours postoperatively
Number of subjects: 114
Study: 30426254

Group type: EXPERIMENTAL
Intervention: Isoperistaltic ileocolic anastomosis (ISO)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Antiperistaltic ileocolic anastomosis (ANTI)
Number of subjects: 108
Study: 28790816

Group type: EXPERIMENTAL
Intervention: Self-management education program (SMEP)
Number of subjects: 0
Study: 25387256

Group type: EXPERIMENTAL
Intervention: Single RFA session (group A; n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Follow-up (group B; n = 42)
Number of subjects: 84
Study: 24500157

Group type: EXPERIMENTAL
Intervention: Complete weight restoration (BMI ≥ 18.5) in patients with AN
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline BSI-GSI score
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study: 23011771

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg once-daily
Number of subjects: 2739
Study: 19670402

Group type: EXPERIMENTAL
Intervention: First night cough recording
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Second night cough recording
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of csec/hr with FEV1%pred on second night
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of csec/hr with FEF(75) %pred on second night
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of bronchiectasis score with mean csec/hr of both nights
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cough frequency during first hour of sleep
Number of subjects: 25
Study: 17178505

Group type: EXPERIMENTAL
Intervention: Anatomic Endodontic Technology (AET) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: ProTaper instruments
Number of subjects: 40
Study: 15134695

Group type: EXPERIMENTAL
Intervention: Glutamate (1 M) injection into the MAR or right SP
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isotonic saline injection into the MAR or SP
Number of subjects: 19
Study: 11157009

Group type: COMPARATOR
Intervention: FEC 50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: FEC 100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 565

Group type: COMPARATOR
Intervention: FEC 50
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: FEC 100
Number of subjects: 565
Study: 9579818

Group type: EXPERIMENTAL
Intervention: Cardiac lesions
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Lowest socioeconomic status
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pericardial effusion
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Higher CD4 count
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Cardiac mass/volume ratio, body temperature, deceleration time, body mass index, socio‐economic status
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Heart involvement
Number of subjects: 157
Study: 7991067

Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 0
Study: 2522008

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg qd, mean 9 mg/d)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 91
Study: 27704326

Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas intervention
Number of subjects: 113
Study: 27146793

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free gum for at least 10 minutes, four times per day on days 1-5)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 402
Study: 24779067

Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 200
Study: 23024150

Group type: EXPERIMENTAL
Intervention: Mosaic-type osteochondral autologous transplantation (OAT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 60
Study: 20513982

Group type: EXPERIMENTAL
Intervention: Mean peak systolic velocity of the superior thyroid artery (STA‐PSV) measured by ultrasonography in untreated Graves' disease (GD) patients.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Mean peak systolic velocity of the superior thyroid artery (STA‐PSV) measured by ultrasonography in treated Graves' disease (GD) patients.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Mean peak systolic velocity of the superior thyroid artery (STA‐PSV) measured by ultrasonography in destructive thyroiditis (DT) patients.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Receiver operating characteristic curves of the STA‐PSV values.
Number of subjects: 161
Study: 17573688

Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prospective control
Number of subjects: 0
Study: 15217778

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 11447800

Group type: EXPERIMENTAL
Intervention: Wound dressing applied after 48 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: No wound dressing applied after 48 hours
Number of subjects: 100
Study: 9728984

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 44

Group type: COMPARATOR
Intervention: No-LCPUFA formula
Number of subjects: 44
Study: 9160549

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2525326

Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg)
Number of subjects: 20
Study: 31207030

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 28416247

Group type: EXPERIMENTAL
Intervention: Adaptive cardiac resynchronization therapy (aCRT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Echo-optimized bi-ventricular CRT (control)
Number of subjects: 199
Study: 26147315

Group type: EXPERIMENTAL
Intervention: Brain Injury Family Intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 108
Study: 23805219

Group type: EXPERIMENTAL
Intervention: Physical activity program (3-month standardized program led by specialists)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 362
Study: 21507028

Group type: EXPERIMENTAL
Intervention: DNK333 25 mg b.d.
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: DNK333 100 mg b.d.
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: DNK333 25 mg b.d. (Trial 2)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo (Trial 2)
Number of subjects: 315
Study: 19690341

Group type: COMPARATOR
Intervention: Advice leaflet
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Dietary intervention plus strengthening exercises
Number of subjects: 389
Study: 17021083

Group type: EXPERIMENTAL
Intervention: High-dose alpha2b interferon (6 million units/day) plus ribavirin (600 to 800 mg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ribavirin (600 to 800 mg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose alpha2b interferon plus ribavirin
Number of subjects: 97
Study: 15663456

Group type: EXPERIMENTAL
Intervention: New supply air filter at high ventilation rate (80% of total airflow)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Used supply air filter at high ventilation rate (80% of total airflow)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: New supply air filter at low ventilation rate (8% of total airflow)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Used supply air filter at low ventilation rate (8% of total airflow)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Increasing outdoor air supply rate with new filter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Increasing outdoor air supply rate with used filter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Replacing used filter with a clean filter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interventions on SBS symptoms and environmental perceptions
Number of subjects: 26
Study: 10981565

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg three times daily for 9 days) + prednisolone (60 mg per day with progressive reduction for 21 days)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Epidural analgesia (6-12 ml bupivacaine (0.25%) every 6-8 or 12 h) + methylprednisolone (40 mg every 3-4 days by epidural catheter for 7 to 21 days)
Number of subjects: 600
Study: 9049576

Group type: EXPERIMENTAL
Intervention: Ibuprofen (7.5 mg/kg per dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (10 mg/kg/dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol (10 mg/kg per dose)
Number of subjects: 0